I studied Biochemistry/Biotechnology at the University of London and then went on to study Biochemistry and Molecular Biology for my PhD in the same institution. The central theme of my research all these years is targeted gene therapy which is one of the most promising solutions for treating life-threatening diseases and its application requires the development of safe carriers to deliver the therapeutic material efficiently and without damage to the target sites within the cells. The main objective of my current research has been to develop and evaluate different non-viral and nanoparticle technologies for gene therapy for cancer, cystic fibrosis, Alzheimer’s disease, conjunctival fibrosis and cardiovascular disorders. These have included a variety of somatic gene transfer approaches towards the efficient, widespread and long-term expression of recombinant genes locally or systemically, silencing of disease-implicated genes, as well as gene repair/editing. Research that I have carried out lead to several publications in leading international journals and a number of collaborations and awards, including the Sir Henry Wellcome Commemorative Postdoctoral Fellowship and the UCL Research Excellence Award. I currently serve as a member of the ‘Physical Delivery, Therapeutics and Vector Development Scientific Committee’ of the American Society of Gene and Cell Therapy. I am a reviewer of grants from different funding bodies and a regular reviewer of many leading scientific journals, serve on editorial boards and a consultant for pharmaceutical companies and small biotech companies.